For example, the “NOT”-gate CD93-CAR-T is an inhibitory CAR strategy designed to mitigate endothelial toxicity generated by CD93-CAR-T cells, which eliminates AML but exerts on-target/off-tumor toxicity to endothelial cells.375 “IF-THEN” gates (which allow spatiotemporal regulation of CAR expression) and “IF-BETTER” gates (in which a CAR-engaging antigen A performs better in the presence of antigen B) are also under investigation.347. This evidence concerns the gene CD93 and acute myeloid leukemia.